Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Files An 8-K Results of Operations and Financial Condition
Item2.02.
|
Results of Operations and Financial Condition. |
On March14, 2017, we issued a press release announcing our
results for the year ended December31, 2016 and will conduct a
previously announced, publicly available conference call to
discuss those results. A copy of this press release is attached
as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference. The information contained on
the websites referenced in the press release is not incorporated
herein.
This information and Exhibit 99.1 hereto shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934 (the Exchange Act) or otherwise subject to the liabilities
of that section, nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933 or the Exchange
Act, except as expressly set forth by specific reference in such
a filing.
| Item9.01. | Financial Statements and Exhibits. |
| (d) | The following exhibit is included in this report: |
|
ExhibitNo. |
Description |
|
| 99.1 | Press release dated March 14, 2017 |
About Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Recent Trading Information
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) closed its last trading session up +0.04 at 2.95 with 812,329 shares trading hands.